PharmaEssentia's blood cancer treatment authorized in Europe

PharmaEssentia, a global biopharmaceutical innovator based in Taiwan, announced on February 23, 2023, that the European Commission has granted marketing authorization for Ropeginterferon alfa-2b for the treatment of Polycythemia Vera (PV) in adult patients who are resistant to hydroxyurea. PV is a chronic, rare blood cancer that causes the bone marrow to produce too many red blood cells, leading to an increased risk of blood clots and other complications.